AstraZeneca to Acquire Alexion for $39B
Shots:
- Alexion to receive $60M in cash and 2.1243 ADSs (each ADS represents ½ ordinary share of AstraZeneca) for each Alexion share. The deal values Alexion at $175/ share with a 45% premium to the closing price on Dec 11- 2020
- Alexion will own ~15% of the combined company. The acquisition will bolster AstraZeneca’s footprints in rare disease and enhance its presence in immunology
- The duo will work together to build Alexion's pipeline of 11 molecules across 20+ clinical- programs in rare diseases and beyond. The new company will lead to a WW expansion of Alexion’s portfolio and is expected to deliver double-digit average annual revenue growth through 2025
Ref: Businesswire | Image: Al Jazeera
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com